3,452
Views
12
CrossRef citations to date
0
Altmetric
Review

A consensus statement for the clinical use of the renal sodium-glucose co-transporter-2 inhibitor dapagliflozin in patients with type 2 diabetes mellitus

, , , , , & show all
Pages 763-772 | Received 12 Jan 2017, Accepted 20 Apr 2017, Published online: 02 May 2017

Reprints and Permissions

Permission is granted subject to the terms of the License under which the work was published. Permission will be required if your reuse is not covered by the terms of the License.

To request a reprint or commercial or derivative permissions for this article, please click on the relevant link below.

For more information please visit our Permissions help page.